Month: July 2021

CHATSWORTH, CA, July 19, 2021 (GLOBE NEWSWIRE) — via NewMediaWire – Cavitation Technologies, Inc. (CVAT and/or “the Company”). (OTCQB: CVAT) (BERLIN: WTC) announced that the Company has completed a financing of $1,500,000 through the sale of approximately 23 million units. Each unit consists of 1 common share of stock and 1 stock purchase warrant exercisable at $.09 per share for a 5-year term. The pricing of the unit represents an approximate 10% premium to the prior 10-day average market close price at the time of the completion of the offering. The units were sold primarily to a group of existing shareholders of the Company.  The Company’s heavily patented technology is being used in collaboration with processes developed by its Joint Venture partner, which is an established and innovative provider of water resources to the...

Figure 1Regional gravity image with gravity highs associated with the Blackwood Prospect and Greenbushes Giant LCT Pegmatite. WA 400m Gravity Merge.Figure 2A Distal pegmatite phase in the Blackwood Prospect, which contains elevated Lithium, Beryllium, Caesium, Rubidium, Tin and Tantalum.Figure 3Blackwood Prospect lies on the Donnybrook Shear Zone which hosts the Greenbushes Mine, shown over the regional RTP 1VD Collie & Pemberton Magnetic Images.Figure 4Blackwood Prospect with NW secondary structures off the Donnybrook Shear Zone, which are likely pegmatite pathways. This is the area of the planned drone survey for September 2021 RTP 1VD Collie Magnetic Image.Figure 5: Sampling at East Kirup Prospect and planned and approved PoW for work for Q4 on the...

Trading expected to begin in the last week of July TORONTO, July 19, 2021 (GLOBE NEWSWIRE) — InterCure Ltd. (TSX: INCR.U, TASE: INCR)(dba Canndoc)(the “Company”) is pleased to announce that further to its confidential filing with the U.S. Securities and Exchange Commission (the “SEC“) of its 20F registration statement on April 20, 2021, it has filed its 20F registration statement pursuant to Securities Exchange Act of 1933 and F-1 registration statement under the Securities Act of 1933. The full statements are available on the Company’s SEDAR profile as well as on EDGAR: 20-F: https://www.sec.gov/Archives/edgar/data/0001857030/000149315221016836/form20fr12b.htm F-1: https://www.sec.gov/Archives/edgar/data/0001857030/000149315221016926/formdrsf-1.htm Listing on the NASDAQ is subject to satisfaction of all applicable...

This new national portal will give JZZ Technologies, Inc. the opportunity to give back to one of the largest communities in need in our country, namely our veterans$JZZI – JZZ Technologies, Inc.Veterans Connect USACalverton, New York , July 19, 2021 (GLOBE NEWSWIRE) — As part of its efforts to connect people in the 55+ age group, JZZ Technologies, Inc. (OTC Pink: JZZI) has launched a new national portal devoted to serving veterans at VeteransConnectUSA.org. The website covers a wide range of information designed to reach veterans and connect them to vital programs, services, and other veterans. The company’s mission is to provide an innovative informational ease-of-use platform that gives veterans the resources that offer opportunities and services they need to prosper and that enable them to reach their...

Prescription Drug User Fee Act (PDUFA) Target Goal Date set for December 23, 2021 If approved by the FDA for U.S. market access, Libervant would be the first orally delivered diazepam product for the management of seizure clustersWARREN, N.J., July 19, 2021 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the resubmission of the New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film for the management of seizure clusters. The FDA has assigned a Prescription Drug User Fee Act (“PDUFA”) target goal date of December 23, 2021. “We are pleased with the FDA’s decision...

BUFFALO, N.Y., July 19, 2021 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and hemp/cannabis research, will host a live webcast on Thursday, August 5, 2021, at 10:00 AM ET to discuss its 2021 second quarter results. 22nd Century will report the Company’s second quarter 2021 results in a press release at 6:00 AM ET the same day. During the webcast, James A. Mish, chief executive officer; Michael Zercher, chief operating officer; and John Franzino, chief financial officer, will review the Company’s 2021 second quarter results, growth opportunities, and innovative strategic plans and future initiatives in the more than $1.3 trillion global addressable markets. Following prepared remarks, including an accompanying...

WEST PALM BEACH, Fla., July 19, 2021 (GLOBE NEWSWIRE) — Rennova Health, Inc. (OTC: RNVA) (OTC: RNVAW), today announced that effective at 5:00 pm, Eastern Time, on July 16, 2021 (the “Effective Time”), the Company effected a 1 for 1,000 reverse stock split of its outstanding common stock. The Company’s common stock will open for trading on Monday, July 19, 2021 on a post-split basis under the temporary trading symbol “RNVAD”. The trading symbol will revert to “RNVA” after 20 business days. As a result of the reverse stock split, every 1,000 shares of the Company’s common stock issued and outstanding on the Effective Time were consolidated into one issued and outstanding share, except to the extent that the reverse stock split resulted in any of the Company’s stockholders owning a fractional share, which fractional share will be...